HRP20192334T1 - Makrociklički inhibitori kinaze rip2 - Google Patents

Makrociklički inhibitori kinaze rip2 Download PDF

Info

Publication number
HRP20192334T1
HRP20192334T1 HRP20192334TT HRP20192334T HRP20192334T1 HR P20192334 T1 HRP20192334 T1 HR P20192334T1 HR P20192334T T HRP20192334T T HR P20192334TT HR P20192334 T HRP20192334 T HR P20192334T HR P20192334 T1 HRP20192334 T1 HR P20192334T1
Authority
HR
Croatia
Prior art keywords
6alkyl
halogen
optionally
independently substituted
substituents
Prior art date
Application number
HRP20192334TT
Other languages
English (en)
Croatian (hr)
Inventor
Jan Hoflack
Petra Blom
Pascal Benderitter
Original Assignee
Oncodesign S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncodesign S.A. filed Critical Oncodesign S.A.
Publication of HRP20192334T1 publication Critical patent/HRP20192334T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20192334TT 2014-09-17 2015-09-17 Makrociklički inhibitori kinaze rip2 HRP20192334T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14185130 2014-09-17
PCT/EP2015/071347 WO2016042087A1 (en) 2014-09-17 2015-09-17 Macrocyclic rip2 kinase inhibitors
EP15766800.5A EP3194407B1 (en) 2014-09-17 2015-09-17 Macrocyclic rip2 kinase inhibitors

Publications (1)

Publication Number Publication Date
HRP20192334T1 true HRP20192334T1 (hr) 2020-03-20

Family

ID=51687776

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20192334TT HRP20192334T1 (hr) 2014-09-17 2015-09-17 Makrociklički inhibitori kinaze rip2

Country Status (26)

Country Link
US (1) US10676486B2 (enExample)
EP (1) EP3194407B1 (enExample)
JP (1) JP6736545B2 (enExample)
KR (1) KR102563829B1 (enExample)
CN (1) CN106687464B (enExample)
AU (1) AU2015316799B2 (enExample)
BR (1) BR112017004035B1 (enExample)
CA (1) CA2958782C (enExample)
DK (1) DK3194407T3 (enExample)
EA (1) EA032872B1 (enExample)
ES (1) ES2763344T3 (enExample)
HR (1) HRP20192334T1 (enExample)
HU (1) HUE048518T2 (enExample)
IL (1) IL250544B (enExample)
LT (1) LT3194407T (enExample)
MX (1) MX376087B (enExample)
MY (1) MY186523A (enExample)
PL (1) PL3194407T3 (enExample)
PT (1) PT3194407T (enExample)
SA (1) SA517381087B1 (enExample)
SG (1) SG11201701116XA (enExample)
SI (1) SI3194407T1 (enExample)
TW (1) TWI709563B (enExample)
UA (1) UA121315C2 (enExample)
WO (1) WO2016042087A1 (enExample)
ZA (1) ZA201701331B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102719387B1 (ko) * 2017-01-26 2024-10-21 한미약품 주식회사 이미다조피리다진 화합물
UY39061A (es) 2020-01-31 2022-01-31 Oncodesign Sa Inhibidores macrocíclicos de rip2-cinasa
CN117659043A (zh) * 2022-09-07 2024-03-08 苏州朗睿生物医药有限公司 一种大环咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途
WO2024146541A1 (en) * 2023-01-03 2024-07-11 Guangdong Newopp Biopharmaceuticals Co., Ltd. Macrocyclic compounds as usp1 inhibitors
WO2025212514A2 (en) * 2024-04-02 2025-10-09 Interline Therapeutics, Inc. Methods of treating inflammatory diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
ES2166786T3 (es) 1993-10-01 2002-05-01 Astrazeneca Ab Procedimiento i.
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
CA2667487C (en) * 2006-11-06 2017-04-04 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2918588B1 (en) * 2010-05-20 2017-05-03 Array Biopharma, Inc. Macrocyclic compounds as TRK kinase inhibitors
WO2013001310A1 (en) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
TWI547494B (zh) * 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
EA025881B1 (ru) * 2011-09-30 2017-02-28 Онкодизайн С.А. Макроциклические ингибиторы flt3-киназы
EP2760453B1 (en) 2011-09-30 2016-05-25 Ipsen Pharma S.A.S. Macrocyclic lrrk2 kinase inhibitors

Also Published As

Publication number Publication date
CA2958782A1 (en) 2016-03-24
CA2958782C (en) 2024-01-09
BR112017004035A8 (pt) 2023-05-09
KR20170048596A (ko) 2017-05-08
UA121315C2 (uk) 2020-05-12
MX2017003469A (es) 2017-05-08
SI3194407T1 (sl) 2020-03-31
SG11201701116XA (en) 2017-03-30
HUE048518T2 (hu) 2020-07-28
US20190127390A1 (en) 2019-05-02
AU2015316799A1 (en) 2017-04-27
ZA201701331B (en) 2020-07-29
EP3194407A1 (en) 2017-07-26
IL250544B (en) 2020-06-30
BR112017004035A2 (pt) 2017-12-05
KR102563829B1 (ko) 2023-08-03
ES2763344T3 (es) 2020-05-28
MY186523A (en) 2021-07-24
DK3194407T3 (da) 2020-01-27
MX376087B (es) 2025-03-07
WO2016042087A1 (en) 2016-03-24
EA201790609A1 (ru) 2017-07-31
IL250544A0 (en) 2017-03-30
BR112017004035B1 (pt) 2023-11-14
TW201619168A (zh) 2016-06-01
PT3194407T (pt) 2020-01-20
SA517381087B1 (ar) 2021-02-09
PL3194407T3 (pl) 2020-04-30
JP2017528481A (ja) 2017-09-28
CN106687464A (zh) 2017-05-17
US10676486B2 (en) 2020-06-09
EA032872B1 (ru) 2019-07-31
EP3194407B1 (en) 2019-10-23
JP6736545B2 (ja) 2020-08-05
NZ730758A (en) 2023-09-29
CN106687464B (zh) 2020-03-03
AU2015316799B2 (en) 2019-07-11
TWI709563B (zh) 2020-11-11
LT3194407T (lt) 2020-01-27

Similar Documents

Publication Publication Date Title
HRP20192334T1 (hr) Makrociklički inhibitori kinaze rip2
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
EP4458348A3 (en) Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
MY169179A (en) Novel piperidine compound or salt thereof
AR107061A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
WO2013076315A3 (en) Substituted n-(tetrazol-5-yl)- and n-(triazol-5-yl)arylcarboxamide compounds and their use as herbicides
AR066171A1 (es) Derivados de nicotinamida, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y usos en la prevencion y/o tratamiento del cancer.
WO2013076316A3 (en) Substituted n-(tetrazol-5-yl)- and n-(triazol-5-yl)hetarylcarboxamide compounds and their use as herbicides
AR103266A1 (es) Compuestos cíclicos sustituidos con un sistema de anillos condensado para combatir plagas de invertebrados
AR113811A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
PH12017501652A1 (en) Kv1.3 inhibitors and their medical application
CY1112679T1 (el) Κινολινες και θεραπευτικη χρηση αυτων
ES2639407T3 (es) Derivados de cianoquinolina
MX2019014406A (es) Compuesto heterociclico y composicion que contiene el mismo.
JP2017529365A5 (enExample)
JP2017528481A5 (enExample)
MX2016017371A (es) Sal de compuesto heterociclico sustituido con halogeno.
AR109949A1 (es) Derivados de fenilamina sustituidos en la posición 4 y uso de los mismos para proteger los cultivos combatiendo los microorganismos fitopatógenos no deseados
MY156539A (en) Phenylimidazole compounds
AR073741A1 (es) Derivados heterociclicos de hidantoina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias, tales como psoriasis o artritis
NZ735032A (en) Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same
AR113991A1 (es) Compuestos de fluoralquenilo, proceso de preparación y uso de los mismos
NO20092804L (no) Kondensert, substituert aminopyrrolidinderivat
ES2659974T3 (es) Compuestos de isotiazolina sustituidos con tiofeno o furano como pesticidas
TNSN08521A1 (en) Phenylpentadienoyl derivatives and their use as par 1 antagonists